Charles A. Watkins II

Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.

Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.

Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors.

Cooley advised Snowflake, the artificial intelligence (AI) Data Cloud company, on its private placement of $2.3 billion aggregate principal amount of convertible senior notes, consisting of $1.15 billion principal amount of convertible senior notes due 2027 and $1.15 billion aggregate principal amount of convertible senior notes due 2029, which includes the exercise in full of the initial purchasers’ options to purchase an additional $150 million principal amount of 2027 notes and $150 million principal amount of 2029 notes. 

Cooley advised BioMarin Pharmaceutical on its $600 million revolving credit agreement with Citibank as administrative agent. BioMarin, which trades on the Nasdaq Global Select Market under the symbol BMRN, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Michael Tollini and Addison Pierce led the Cooley team.